Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMFX-200S
- Development stage
- Preclinical
- Lead developer
- Amphix Bio
- Modality
- Peptides
01
Overview
AMFX-200S is a preclinical-stage supramolecular therapeutic peptide (STP) being developed by Amphix Bio for the treatment of ischemic stroke and amyotrophic lateral sclerosis (ALS). The drug is composed of self-assembling peptide amphiphile molecules that form nanostructure scaffolds upon administration. These scaffolds are designed to mimic the natural extracellular matrix, thereby activating regenerative signaling pathways and providing structural support to facilitate tissue repair and neuroprotection. Unlike conventional targeted therapies, AMFX-200S utilizes a biomimetic approach to modulate the cellular environment rather than binding to a single specific molecular receptor.
- Other names
- AMFX-200SAMFX200SAMFX 200S
Beyond the preview
Go deeper on AMFX-200S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMFX-200S.